MP
OVID icon

Mangrove Partners’s Ovid Therapeutics OVID Stock Holding History

Mangrove Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.6K Buy
+27,294
New +$48.8K ﹤0.01% 410

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Mangrove Partners's OVID Position: Q1 2026 in Review

Mangrove Partners opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 27,294 shares worth $60.6K. The stake represents ﹤0.01% of the portfolio and ranks #410 among its holdings.

103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Mangrove Partners held 27,294 shares of Ovid Therapeutics worth $60.6K as of Q1 2026.
  • Ovid Therapeutics was a new Mangrove Partners position in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Mangrove Partners's portfolio in Q1 2026, its #410 holding.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.